License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 11, 2021	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2020	Dec. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment received			$ 625,000
Accrued expenses and other current liabilities		$ 13,806	13,806		$ 17,157
License and collaboration revenue		41,716	194,238
Deferred Revenue		85,987	85,987		280,225
Adimab L L C
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum additional receivable based on achievement of research milestones			14,500	$ 1,000
Additional Milestone Payment Accrued		2,000	2,000
Adimab L L C | License revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and collaboration revenue			3,400
Adimab L L C | Development Regulatory and Sales Milestone
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum option fees receivable based on achievement of research milestones		45,800	$ 45,800
GSK
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment received	$ 625,000
Milestone payments	$ 1,450,000
Costs related to global development plan			60.00%
Costs related to the cost-sharing provisions		5,200	$ 10,500
Accounts payable for license agreement costs incurred		2,600	2,800
Accrued expenses and other current liabilities		2,600	2,600
Due to related parties					3,000
Related party transaction, expenses from transactions with related party			900,000
Eligible royalty payments percentage	20.00%
Deferred Revenue		86,000	86,000		$ 280,200
Capitalized contract cost		6,800	6,800
GSK | License revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and collaboration revenue		$ 41,700	$ 194,200